Academic Journal
Utility of 21-Gene Recurrence Score in Male Breast Cancer.
| Τίτλος: | Utility of 21-Gene Recurrence Score in Male Breast Cancer. |
|---|---|
| Συγγραφείς: | Hager MG; Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA., Hoskin TL; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA., Ruddy KJ; Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA., Boughey JC; Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA. Boughey.Judy@mayo.edu. |
| Πηγή: | Annals of surgical oncology [Ann Surg Oncol] 2026 Aug; Vol. 33 (8), pp. 7229-7236. Date of Electronic Publication: 2026 May 11. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer Country of Publication: United States NLM ID: 9420840 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1534-4681 (Electronic) Linking ISSN: 10689265 NLM ISO Abbreviation: Ann Surg Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2005- : New York, NY : Springer Original Publication: New York, NY : Raven Press, c1994- |
| Ιατρικοί όροι (MeSH): | Breast Neoplasms, Male*/genetics , Breast Neoplasms, Male*/pathology , Breast Neoplasms, Male*/drug therapy , Neoplasm Recurrence, Local*/genetics , Neoplasm Recurrence, Local*/pathology , Neoplasm Recurrence, Local*/drug therapy , Biomarkers, Tumor*/genetics , Gene Expression Profiling*/methods, Erb-b2 Receptor Tyrosine Kinases/metabolism ; Humans ; Male ; Survival Rate ; Prognosis ; Aged ; Middle Aged ; Female ; Follow-Up Studies |
| Περίληψη: | Background: Recurrence score (RS) is a 21-gene analysis (Oncotype DX) that assesses risk of breast cancer recurrence and benefit from chemotherapy. While extensively validated in female patients, RS has not been well studied in male patients. Patients and Methods: Using the National Cancer Database (NCDB) we identified patients with pT1-2, N0-1 estrogen receptor (ER)+ human epidermal growth factor (HER)2- breast cancer (2010-2023) to assess RS usage and prognostic implications. Groups were compared using chi-squared tests. Overall survival (OS) was analyzed using multivariable Cox proportional hazards regression. Results: We identified 9908 male and 1,111,898 female patients. While overall rate of RS testing was lower in male (42%) than female (46%) patients, RS use increased markedly between 2010 and 2023 (18-66% in male and 28-62% in female patients), and in 2023, the rate was slightly higher for male patients (p = 0.04). Among those tested, male patients were more likely to have RS ≥ 26 (19% versus 14%, p < 0.001). From 2019 to 2023, chemotherapy use in patients with RS ≥ 26 was lower in male than female patients (68% versus 77%, p < 0.001). Male patients with RS ≥ 26 had significantly poorer OS if chemotherapy was omitted (aHR 1.5, p = 0.03), with a larger difference for male patients aged < 65 years (82% versus 93% 5-year OS without versus with chemotherapy, p = 0.009) than for male patients ≥ 65 years (75% versus 84%, respectively, p = 0.28). Conclusions: RS testing increased between 2010 and 2023 for both sexes, and RS influenced receipt of chemotherapy. Male patients had higher RS but were less likely to receive chemotherapy when RS ≥ 26, and when chemotherapy was omitted, they had worse OS, revealing the importance of chemotherapy among males with high RS. (© 2026. Society of Surgical Oncology.) |
| References: | Saad Abdalla Al-Zawi A. The Oncotype DX Recurrence score impact on the management of ER-positive, HER2-negative, node-negative breast cancer. Med Res J. 2021;6(3):211-216. https://doi.org/10.5603/MRJ.a2021.0041 . Paik S, Shak S, Tang G, al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–26. https://doi.org/10.1056/NEJMoa041588 . Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor–positive breast cancer. J Clin Oncol. 2006;24(23):3726–34. https://doi.org/10.1200/JCO.2005.04.7985 . (PMID: 10.1200/JCO.2005.04.798516720680) Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111–21. https://doi.org/10.1056/NEJMoa1804710 . (PMID: 10.1056/NEJMoa1804710298609176172658) Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336–47. https://doi.org/10.1056/NEJMoa2108873 . (PMID: 10.1056/NEJMoa2108873349143399096864) American Cancer Society. Breast Cancer Facts & Figures 2024-2025. American Cancer Society, 2024. PDF file. National Comprehensive Cancer Network. Breast Cancer. NCCN Clinical Practice Guidelines in Oncology, Version 2025.10.16. National Comprehensive Cancer Network, 16 Oct. 2025. Williams AD, McGreevy CM, Tchou JC, De La Cruz LM. Utility of oncotype DX in male breast cancer patients and impact on chemotherapy administration: a comparative study with female patients. Ann Surg Oncol. 2020;27(10):3605–11. https://doi.org/10.1245/s10434-020-08473-y . (PMID: 10.1245/s10434-020-08473-y32472417) Wang F, Reid S, Zheng W, et al. Sex disparity observed for oncotype DX breast recurrence score in predicting mortality among patients with early stage ER-positive breast cancer. Clin Cancer Res. 2020;26(1):101–9. https://doi.org/10.1158/1078-0432.CCR-19-2424 . (PMID: 10.1158/1078-0432.CCR-19-242431748278) Habermann EB, Day CN, Palis BE, et al. American College of Surgeons Cancer Program Annual Report from 2021 Participant User File. J Am Coll Surg. 2025;240(1):95–110. https://doi.org/10.1097/XCS.0000000000001214 . (PMID: 10.1097/XCS.000000000000121439625171) Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med. 1984;3(1):35–44. https://doi.org/10.1002/sim.4780030106 . (PMID: 10.1002/sim.47800301066729287) Yadav S, Karam D, Bin Riaz I, et al. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. Cancer. 2020;126(1):26–36. https://doi.org/10.1002/cncr.32472 . (PMID: 10.1002/cncr.3247231588557) Altman AM, Kizy S, Yuan J, et al. Distribution of 21-gene recurrence scores in male breast cancer in the United States. Ann Surg Oncol. 2018;25(8):2296–302. https://doi.org/10.1245/s10434-018-6566-7 . (PMID: 10.1245/s10434-018-6566-729907942) Dubrovsky E, Raymond S, Chun J, et al. Genomic testing in early-stage invasive male breast cancer: an NCDB analysis from 2008 to 2014. Breast J. 2019;25(3):425–33. https://doi.org/10.1111/tbj.13235 . (PMID: 10.1111/tbj.1323531025517) Massarweh SA, Sledge GW, Miller DP, McCullough D, Petkov VI, Shak S. Molecular characterization and mortality from breast cancer in men. J Clin Oncol. 2018;36(14):1396–404. https://doi.org/10.1200/JCO.2017.76.8861 . (PMID: 10.1200/JCO.2017.76.8861295845476075854) Giordano SH. Breast cancer in men. N Engl J Med. 2018;378(24):2311–20. https://doi.org/10.1056/NEJMra1707939 . (PMID: 10.1056/NEJMra170793929897847) Henry NL, Somerfield MR, Abramson VG, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: update of the ASCO Endorsement of the Cancer Care Ontario Guideline. J Clin Oncol. 2019;37(22):1965–77. https://doi.org/10.1200/JCO.19.00948 . (PMID: 10.1200/JCO.19.0094831206315) Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO Guideline. J Clin Oncol. 2020;38(16):1849–63. https://doi.org/10.1200/JCO.19.03120 . (PMID: 10.1200/JCO.19.0312032058842) |
| Contributed Indexing: | Keywords: 21-gene analysis; Breast cancer recurrence; Male breast cancer; OncotypeDX; Recurrence score |
| Substance Nomenclature: | 0 (Biomarkers, Tumor) EC 2.7.10.1 (Erb-b2 Receptor Tyrosine Kinases) |
| Entry Date(s): | Date Created: 20260511 Date Completed: 20260707 Latest Revision: 20260707 |
| Update Code: | 20260708 |
| DOI: | 10.1245/s10434-026-19779-8 |
| PMID: | 42113374 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!